A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant

C. Bétry, D. Overstreet, N. Haddjeri, Alan Pehrson, C. Bundgaard, C. Sanchez, A. Mørk

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

More effective treatments for major depression are needed. We studied if the selective 5-HT3 receptor antagonist ondansetron can potentiate the antidepressant potential of the selective serotonin (5-HT) reuptake inhibitor (SSRI) paroxetine using behavioral, neurochemical and electrophysiological methods. Flinders Sensitive Line (FSL) rats, treated with ondansetron, and/or a sub-effective dose of paroxetine, were assessed in the forced swim test. The effects of an acute intravenous administration of each compound alone and in combination were evaluated with respect to 5-HT neuronal firing rate in the dorsal raphe nucleus (DRN). Effects of s.c. administration of the compounds alone and in combination on extracellular levels of 5-HT were assessed in the ventral hippocampus of freely moving rats by microdialysis. The results showed that ondansetron enhanced the antidepressant activity of paroxetine in the forced swim test. It partially prevented the suppressant effect of paroxetine on DRN 5-HT neuronal firing and enhanced the paroxetine-induced increase of hippocampal extracellular 5-HT release. These findings indicate that 5-HT3 receptor blockade potentiates the antidepressant effects of SSRIs. Since both paroxetine and ondansetron are used clinically, it might be possible to validate this augmentation strategy in depressed patients.

Original languageEnglish
Pages (from-to)136-142
Number of pages7
JournalPharmacology Biochemistry and Behavior
Volume131
DOIs
StatePublished - 1 Jan 2015

Fingerprint

Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Paroxetine
Antidepressive Agents
Ondansetron
Serotonin
Rats
Microdialysis
Intravenous Administration
Hippocampus

Keywords

  • 5-HT receptor
  • Antidepressants
  • Major depressive disorder
  • Ondansetron
  • Paroxetine

Cite this

Bétry, C. ; Overstreet, D. ; Haddjeri, N. ; Pehrson, Alan ; Bundgaard, C. ; Sanchez, C. ; Mørk, A. / A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant. In: Pharmacology Biochemistry and Behavior. 2015 ; Vol. 131. pp. 136-142.
@article{78d9a5bc32894f80a5283eb9a77931c4,
title = "A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant",
abstract = "More effective treatments for major depression are needed. We studied if the selective 5-HT3 receptor antagonist ondansetron can potentiate the antidepressant potential of the selective serotonin (5-HT) reuptake inhibitor (SSRI) paroxetine using behavioral, neurochemical and electrophysiological methods. Flinders Sensitive Line (FSL) rats, treated with ondansetron, and/or a sub-effective dose of paroxetine, were assessed in the forced swim test. The effects of an acute intravenous administration of each compound alone and in combination were evaluated with respect to 5-HT neuronal firing rate in the dorsal raphe nucleus (DRN). Effects of s.c. administration of the compounds alone and in combination on extracellular levels of 5-HT were assessed in the ventral hippocampus of freely moving rats by microdialysis. The results showed that ondansetron enhanced the antidepressant activity of paroxetine in the forced swim test. It partially prevented the suppressant effect of paroxetine on DRN 5-HT neuronal firing and enhanced the paroxetine-induced increase of hippocampal extracellular 5-HT release. These findings indicate that 5-HT3 receptor blockade potentiates the antidepressant effects of SSRIs. Since both paroxetine and ondansetron are used clinically, it might be possible to validate this augmentation strategy in depressed patients.",
keywords = "5-HT receptor, Antidepressants, Major depressive disorder, Ondansetron, Paroxetine",
author = "C. B{\'e}try and D. Overstreet and N. Haddjeri and Alan Pehrson and C. Bundgaard and C. Sanchez and A. M{\o}rk",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.pbb.2015.02.011",
language = "English",
volume = "131",
pages = "136--142",
journal = "Pharmacology, Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant. / Bétry, C.; Overstreet, D.; Haddjeri, N.; Pehrson, Alan; Bundgaard, C.; Sanchez, C.; Mørk, A.

In: Pharmacology Biochemistry and Behavior, Vol. 131, 01.01.2015, p. 136-142.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A 5-HT3 receptor antagonist potentiates the behavioral, neurochemical and electrophysiological actions of an SSRI antidepressant

AU - Bétry, C.

AU - Overstreet, D.

AU - Haddjeri, N.

AU - Pehrson, Alan

AU - Bundgaard, C.

AU - Sanchez, C.

AU - Mørk, A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - More effective treatments for major depression are needed. We studied if the selective 5-HT3 receptor antagonist ondansetron can potentiate the antidepressant potential of the selective serotonin (5-HT) reuptake inhibitor (SSRI) paroxetine using behavioral, neurochemical and electrophysiological methods. Flinders Sensitive Line (FSL) rats, treated with ondansetron, and/or a sub-effective dose of paroxetine, were assessed in the forced swim test. The effects of an acute intravenous administration of each compound alone and in combination were evaluated with respect to 5-HT neuronal firing rate in the dorsal raphe nucleus (DRN). Effects of s.c. administration of the compounds alone and in combination on extracellular levels of 5-HT were assessed in the ventral hippocampus of freely moving rats by microdialysis. The results showed that ondansetron enhanced the antidepressant activity of paroxetine in the forced swim test. It partially prevented the suppressant effect of paroxetine on DRN 5-HT neuronal firing and enhanced the paroxetine-induced increase of hippocampal extracellular 5-HT release. These findings indicate that 5-HT3 receptor blockade potentiates the antidepressant effects of SSRIs. Since both paroxetine and ondansetron are used clinically, it might be possible to validate this augmentation strategy in depressed patients.

AB - More effective treatments for major depression are needed. We studied if the selective 5-HT3 receptor antagonist ondansetron can potentiate the antidepressant potential of the selective serotonin (5-HT) reuptake inhibitor (SSRI) paroxetine using behavioral, neurochemical and electrophysiological methods. Flinders Sensitive Line (FSL) rats, treated with ondansetron, and/or a sub-effective dose of paroxetine, were assessed in the forced swim test. The effects of an acute intravenous administration of each compound alone and in combination were evaluated with respect to 5-HT neuronal firing rate in the dorsal raphe nucleus (DRN). Effects of s.c. administration of the compounds alone and in combination on extracellular levels of 5-HT were assessed in the ventral hippocampus of freely moving rats by microdialysis. The results showed that ondansetron enhanced the antidepressant activity of paroxetine in the forced swim test. It partially prevented the suppressant effect of paroxetine on DRN 5-HT neuronal firing and enhanced the paroxetine-induced increase of hippocampal extracellular 5-HT release. These findings indicate that 5-HT3 receptor blockade potentiates the antidepressant effects of SSRIs. Since both paroxetine and ondansetron are used clinically, it might be possible to validate this augmentation strategy in depressed patients.

KW - 5-HT receptor

KW - Antidepressants

KW - Major depressive disorder

KW - Ondansetron

KW - Paroxetine

UR - http://www.scopus.com/inward/record.url?scp=84923374782&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2015.02.011

DO - 10.1016/j.pbb.2015.02.011

M3 - Article

VL - 131

SP - 136

EP - 142

JO - Pharmacology, Biochemistry and Behavior

JF - Pharmacology, Biochemistry and Behavior

SN - 0091-3057

ER -